Regeneron Pharmaceuticals | Des Atouts



Assets Changement Date
AbbVie USD 136.17B 1B 2025-03
Agios Pharmaceuticals USD 1.47B 84.28M 2025-06
Alnylam Pharmaceuticals USD 4.57B 352.21M 2025-06
Amgen USD 87.9B 1.47B 2025-06
Astellas Pharma JPY 3.34T 3.71B 2025-06
AstraZeneca USD 112.42B 6.17B 2025-06
Biogen USD 28.33B 297.1M 2025-06
BioMarin Pharmaceutical USD 7.46B 309.33M 2025-06
Bristol-Myers Squibb USD 94.68B 2.25B 2025-06
Eli Lilly USD 100.92B 11.53B 2025-06
Gilead Sciences USD 55.72B 713M 2025-06
GlaxoSmithKline GBP 59.26B 1.45B 2025-06
Incyte USD 5.82B 71.99M 2025-06
Ionis Pharmaceuticals USD 2.99B 172.18M 2025-06
J&J USD 193.67B 13.57B 2025-03
Kyowa Hakko Kirin JPY 1.07T 47.23B 2025-06
Merck USD 117.52B 2.4B 2025-06
Moderna USD 12.01B 694M 2025-06
Neurocrine Biosciences USD 3.89B 202.1M 2025-06
Novartis USD 104.4B 4.45B 2025-06
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 206.1B 1.93B 2025-06
Regeneron Pharmaceuticals USD 38.22B 674M 2025-06
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 132.8B 3.04B 2024-12
Sarepta Therapeutics USD 3.68B 214.43M 2025-06
Teva Pharmaceutical Industries USD 40.13B 1.72B 2025-06
Ultragenyx Pharmaceutical USD 1.31B 5.66M 2025-06
United Therapeutics USD 7.91B 164.1M 2025-06
Vertex Pharmaceuticals USD 24.04B 1.16B 2025-06


Regeneron Pharmaceuticals Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.